Liposomal Amphotericin B for Invasive Candida Infection
Liposomal amphotericin B at 3-5 mg/kg daily is indicated primarily for CNS candidiasis (meningitis), neonatal disseminated candidiasis (as an alternative), and as salvage therapy when echinocandins or fluconazole cannot be used due to resistance or toxicity. 1
Primary Indications
CNS Candidiasis (Strongest Indication)
- Liposomal amphotericin B 5 mg/kg daily is the alternative initial treatment for Candida meningitis (strong recommendation) 1
- AmB deoxycholate 1 mg/kg daily remains first-line, but liposomal formulation offers equivalent efficacy with superior tolerability
- Continue until all CSF abnormalities, symptoms, and radiological findings resolve
- Remove infected CNS devices (ventriculostomy drains, shunts) whenever possible
Neonatal Disseminated Candidiasis
- Lipid formulation AmB 3-5 mg/kg daily is an alternative when AmB deoxycholate or fluconazole cannot be used (weak recommendation) 1
- Critical caveat: Use with extreme caution in urinary tract involvement - lipid formulations achieve poor urinary concentrations
- AmB deoxycholate 1 mg/kg daily remains preferred first-line (strong recommendation)
- Fluconazole 12 mg/kg daily is reasonable if no prior fluconazole prophylaxis
Cardiac Involvement
- For native valve endocarditis: lipid formulation AmB 3-5 mg/kg daily with or without flucytosine 25 mg/kg four times daily 1
- High-dose echinocandins are alternatives
- Surgical intervention typically required
When NOT to Use Liposomal Amphotericin B
Standard Candidemia/Invasive Candidiasis
Echinocandins are first-line, NOT liposomal amphotericin B 1
- Caspofungin: 70 mg loading, then 50 mg daily
- Anidulafungin: 200 mg loading, then 100 mg daily
- Micafungin: 100 mg daily
- Fluconazole 800 mg loading, then 400 mg daily is acceptable in non-critically ill patients without prior azole exposure
Intra-abdominal Candidiasis
Treatment follows same algorithm as candidemia - echinocandins or fluconazole, NOT liposomal amphotericin B as first-line 1
Dosing Regimens
Standard Dosing
- 3-5 mg/kg daily for most invasive Candida infections 1, 2
- 5 mg/kg daily specifically for CNS infections 1
Evidence on Lower Dosing
Recent research suggests 1 mg/kg daily may be equally effective for many indications with comparable clinical outcomes and toxicity 3, though this contradicts guideline recommendations and should be reserved for resource-limited settings or when standard dosing is not tolerated.
Higher Dosing
The AmBiLoad trial showed no benefit of 10 mg/kg daily over 3 mg/kg daily for invasive mould infections, with increased nephrotoxicity at higher doses 4. Do not exceed standard dosing.
Critical Clinical Considerations
Urinary Tract Involvement
Major pitfall: Lipid formulations achieve poor urinary concentrations 1
- For Candida cystitis or pyelonephritis, use fluconazole (if susceptible) or AmB deoxycholate
- Lipid formulations are specifically cautioned against in neonates with urinary involvement
Comparative Tolerability
Liposomal amphotericin B offers:
- Significantly reduced nephrotoxicity compared to AmB deoxycholate 5, 4, 6
- Fewer infusion-related reactions than AmB deoxycholate or ABCD 5, 4
- More nephrotoxicity and infusion reactions than echinocandins 4
Duration of Therapy
- Candidemia without metastatic complications: 2 weeks after blood culture clearance and symptom resolution 1
- CNS involvement: Continue until all CSF, clinical, and radiological abnormalities resolve 1
- Endocarditis: Prolonged therapy (weeks to months) with surgical intervention
Practical Algorithm
Step 1: Identify infection site
- CNS → Liposomal AmB 5 mg/kg daily (or AmB deoxycholate 1 mg/kg)
- Cardiac → Lipid AmB 3-5 mg/kg ± flucytosine
- Urinary tract → Avoid lipid formulations; use fluconazole or AmB deoxycholate
- Bloodstream/visceral → Echinocandin first-line
Step 2: Consider patient-specific factors
- Neonates with disseminated disease → AmB deoxycholate preferred; lipid formulation if toxicity/resistance
- Renal impairment → Lipid formulation preferred over AmB deoxycholate
- Prior azole exposure → Echinocandin over fluconazole
Step 3: Source control
- Remove central venous catheters 1
- Drain abscesses, remove infected devices
- Surgical intervention for endocarditis
The evidence strongly supports that liposomal amphotericin B is NOT first-line for most invasive Candida infections - echinocandins hold that position. Its role is specifically for CNS disease, as an alternative in neonates, and when other agents fail or cannot be used.